Abstract
Pemetrexed is antifolátové antineoplastic agent that has shown efficacy in the treatment of non-small cell lung cancer (NSCLC). Currently in clinical practice used in four indications, ie in the first-line treatment of malignant pleural mesothelioma in the first line, in maintenance therapy and in second-line treatment of non-small cell lung cancer.
Pemetrexed demonstrated consistently higher efficacy in neskvamózních tumor types. Latest results for the indication of maintenance therapy brought new insights to standard treatment regimens NSCLC.